NCT05850234: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 2 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05850234 |
|---|---|
| Title | A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 20, 2023 |
| Completion date | Aug. 31, 2027 |
| Required reporting date | Aug. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |